Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease

Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease - Effect of Haemodialysis on the Plasma glucose profile and Plasma level of Liraglutide in People with Type 2 Diabetes Mellitus and End Stage Renal Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010159

Enrollment

Registered

2013-03-08

Start date

2013-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Male and female subjects with type 2 Diabetes Mellitus 2.Age &#8805;20 years 3.Treated with stable dose of liraglutide of 0.6mg or 0.9mg for at least 2 weeks. 4.GA 30% or less 5.Able to provide informed consent before any trial-related activities.

Exclusion criteria

Exclusion criteria: 1-Type 1 Diabetes Mellitus 2-Previous treatment with other incretin mimetics within the previous three months before screening. 3-Insulin-requiring type 2 Diabetes Mellitus 4-Impaired hepatic function, measured as serum glutamic oxaloacetic transaminase [sGOT ( Aspartate Aminotransferase , ASAT)] or serum glutamic pyruvic transaminase (sGPT) &#8805; 100 IU/L 5-Unstable cardiovascular or cerebrovascular disease. 6-Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures. 7-Female of childbearing potential who are not using adequate contraceptive menthods 8-Known or suspected allergy to trial medication(s), excipients, or related products. 9-Any contraindications to liraglutide.

Design outcomes

Primary

Measure	Time frame
Plasma glucose profile (CGM) on-haemodialysis and off-haemodialysis	—

Secondary

Measure	Time frame
Plasma liragutide levels while on-haemodialysis and off-haemodialysis	—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Nakakinen Clinic Director

k-ofuchi@kensei-kai.com029-353-2800

Outcome results